Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.
The Boston Globe14d
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...
The Business Journals15d
Vertex wins FDA approval for long-awaited non-opioid painkiller
The Boston drugmaker (Nasdaq: VRTX) says it put more than two decades of work into developing and bringing the new medicine to market. Stuart Arbuckle, Vertex’s chief operating officer ...
Business Wire1mon
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P ...
Pharmabiz14d
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain
Vertex Pharmaceuticals Incorporated, an American biopharmaceutical company based in Boston, announced that the US Food and Drug Administration (FDA) has approved its Journavx (suzetrigine), an oral, ...